Tag Archive for: SAB

Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments

Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief Scientific Officer Janine Schuurman, PhD, Hans Clevers, MD, PhD, and David Sansom, PhD, join the Scientific Advisory Board Appointments strengthen Laigo’s leadership team following its €17m seed financing as the Company advances its SureTACs™ programs towards clinical development UTRECHT, […]

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)

Lead programme based on a first‑in‑class small‑molecule E6AP ubiquitin ligase inhibition strategy for the treatment of HPV‑positive head and neck cancer Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027 Progress is complemented with formation of world-class SAB, including leading experts in E3 […]

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug development Appointments strengthen Rewind’s clinical experience as its GPR17 remyelination therapy advances toward clinical trials Leuven, Belgium – 18 June 2025 – Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, […]

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on […]